The Apalutamide study presented in SF recently was published in the NEJM yesterday . The comparable Xtandi study paper is still in peer review. Score one for Apalutamide.
The NEJM link is to the full text. I expect that some will be interested in the details.
Others might prefer the NY Times story .
"Dr. Sartor and others noted that another androgen receptor inhibitor, abiraterone, which is used to treat cancer once it metastasizes and is also produced by Janssen, is likely to go off-patent soon and will become much cheaper because generic versions will be produced."
Note that Abiraterone Acetate (Zytiga) is a steroidal CYP17A1 inhibitor - not a direct androgen receptor [AR] inhibitor. The confusion is probably due to the fact that hormonal therapy in all its forms ultimately targets AR.